Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Cantor Fitzgerald
Queensland Health
Cipla
Dow
Fuji
AstraZeneca
Accenture
Julphar

Generated: October 15, 2018

DrugPatentWatch Database Preview

Lisinopril - Generic Drug Details

« Back to Dashboard

What are the generic sources for lisinopril and what is the scope of lisinopril patent protection?

Lisinopril is the generic ingredient in four branded drugs marketed by Silvergate Pharms, Accord Hlthcare, Apotex Inc, Aurobindo, Casi Pharms Inc, Hikma Intl Pharms, Invagen Pharms, Ivax Sub Teva Pharms, Lupin, Mylan, Prinston Inc, Sandoz, Sun Pharm Inds Ltd, Teva, Watson Labs, Wockhardt, Merck, and Alvogen Malta, and is included in twenty-one NDAs. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

There are twenty-one drug master file entries for lisinopril. Eighty-one suppliers are listed for this compound.

Pharmacology for lisinopril
Medical Subject Heading (MeSH) Categories for lisinopril
Synonyms for lisinopril
(2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-phenyl-propyl]amino]hexanoyl]proline;hydrate
(2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-phenyl-propyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid
(2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]-1-oxohexyl]-2-pyrrolidinecarboxylic acid
(2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]-1-oxohexyl]-2-pyrrolidinecarboxylic acid;hydrate
(2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid;hydrate
(2S)-1-[(2S)-6-amino-2-[[(2S)-1-hydroxy-1-oxo-4-phenylbutan-2-yl]amino]hexanoyl]pyrrolidine-2-carboxylic acid
(2S)-1-[(2S)-6-amino-2-{[(1S)-1-carboxy-3-phenylpropyl]amino}hexanoyl]pyrrolidine-2-carboxylic acid
(2S)-1-[(2S)-6-azanyl-2-[[(2S)-1-oxidanyl-1-oxidanylidene-4-phenyl-butan-2-yl]amino]hexanoyl]pyrrolidine-2-carboxylic acid
(2S)-1-[(2S)-6-azanyl-2-[[(2S)-1-oxidanyl-1-oxidanylidene-4-phenyl-butan-2-yl]amino]hexanoyl]pyrrolidine-2-carboxylic acid;hydrate
(S)-1-((S)-6-Amino-2-(((S)-1-carboxy-3-phenylpropyl)amino)hexanoyl)pyrrolidine-2-carboxylic acid
(S)-1-(N(2)-(1-carboxy-3-phenylpropyl)-L-lysyl)-L-proline
(S)-1-(N(sup 2)-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline
(S)-1-(N2-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline
(S)-1-(N2-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline dihydrate
(S)-1-[(S)-6-AMINO-2-((S)-1-CARBOXY-3-PHENYL-PROPYLAMINO)-HEXANOYL]-PYRROLIDINE-2-CARBOXYLIC ACID
(S)-1-[N2-(1-carboxy-3-phenylpropyl)-L-lysyl]-L-proline dihydrate
(S)-1-[N2-(1-Carboxy-3-phenylpropyl)-lysyl-proline dihydrate
(S)-NALPHA-(1-CARBOXY-3-PHENYLPROPYL)-LYS-PRO
[N2-[(S)-1-CARBOXY-3-PHENYLPROPYL]-L-LYSYL-L-PROLINE
1-(N2-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline
1-[Nalpha-[(S)-1-Carboxy-3-phenylpropyl]-L-lysyl]-L-proline
1835AH
2517AH
54256-EP2270011A1
54256-EP2272834A1
54256-EP2277879A1
54256-EP2287165A2
54256-EP2287166A2
54256-EP2292228A1
54256-EP2292620A2
54256-EP2298742A1
54256-EP2298776A1
54256-EP2298779A1
54256-EP2301923A1
54256-EP2301929A1
54256-EP2301931A1
54256-EP2301935A1
54256-EP2305648A1
54256-EP2305674A1
54256-EP2308562A2
547L983
76547-98-3
77726-95-5
7Q3P4BS2FD
83915-83-7
83915-83-7 (Parent)
A838743
AB00052250_14
AB00052250_15
AB00052250-13
AB04852
AC1NSFPF
Acerbon
Acercomp
AK322582
AKOS015836369
AKOS015894970
Alapril
Amicor
AN-36890
anhydrous lisinopril
BB_NC-1454
BCP9000856
BDBM50367879
BDBM66979
BIDD:GT0755
BPBio1_000290
BRD-K67966701-335-03-5
BRN 4276619
BSPBio_000262
C21H31N3O5
Carace
CCG-39190
CCRIS 3568
CHEBI:43755
CHEMBL1237
cid_22887897
Cipral
Coric
CPD000544473
CS-2443
CTK5F1429
D07HGR
D08131
DB00722
Diroton
DivK1c_001037
DL-434
Doneka
DTXSID6040537
EINECS 278-488-1
FT-0627878
GTPL6360
Hipril
Hipril (TN)
HMS1921B14
HMS2090O14
HMS2092L21
HMS2850N20
HMS503O15
HSDB 6852
HY-18206
I06-1895
ICI-209K
IDI1_001037
Inhibril
Inopril
Irumed
KBio1_001037
KBio2_000977
KBio2_003545
KBio2_006113
KBio3_002002
KBioGR_001599
KBioSS_000977
KM1776
KS-00000GHQ
KSC651I2T
L-Proline, 1-(N(sup 2)-(1-carboxy-3-phenylpropyl)-L-lysyl)-, (S)-
L-Proline, 1-(N2-(1-carboxy-3-phenylpropyl)-L-lysyl)-
L-Proline, 1-(N2-(1-carboxy-3-phenylpropyl)-L-lysyl)-, (S)-
L-Proline, N2-((1S)-1-carboxy-3-phenylpropyl)-L-lysyl-
L0220
Laaven
Linopril
Linvas
Lipril
Lisinal
Lisinopril (anhydrous)
Lisinopril (INN)
Lisinopril (Zestril)
Lisinopril [INN]
Lisinopril anhydrous
Lisinopril hydrate
Lisinoprilum
Lisinoprilum [Latin]
Lisipril
Lisitec
Lisopril
Lisoril
Lispril
Listril
Lizinopril
Lizonoton
Longes
Loril
LPR
LS-118899
Lysinopril
lysinopryl
MCULE-7813362088
MFCD01698825
MK 521
MK 522
MK-521
MLS001306436
MLS001306481
MLS002154258
MolPort-002-507-428
N-(1(S)-Carboxy-3-phenylpropyl)-L-lysyl-L-proline
N-[N2 -(1(S)-carboxy-3-phenylpropyl)-L-lysyl]-L-proline
N-[N2 (1(S)-carboxy-3-phenylpropyl)-L-lysyl]-L-proline
N(2)-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline
N2-((S)-1-Carboxy-3-phenylpropyl)-L-lysyl-L-proline
N2-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline
Nanopril
NCGC00179623-01
NINDS_001037
Noperten
Novatec
NSC-751176
NSC-758151
NSC751176
NSC758151
Optimon
Pharmakon1600-01501217
Presiten
Prestwick0_000301
Prestwick1_000301
Prestwick2_000301
Prestwick3_000301
Prinil
Prinivil
Prinivil (TN)
Prinvil
Qbrelis
RLAWWYSOJDYHDC-BZSNNMDCSA-N
s2076
SAM002589993
SBI-0051692.P002
SC-18165
SCHEMBL15680
Sinopril
Sinopryl
Skopryl
SMR000544473
SMR001233519
SPBio_001351
SPBio_002481
Spectrum_000497
SPECTRUM1501217
Spectrum2_001456
Spectrum3_000941
Spectrum4_001040
Spectrum5_000995
SR-05000001786
SR-05000001786-1
Tensopril
Tensopril (TN)
Tensyn
Tersif
TL8005499
UNII-7Q3P4BS2FD
Vitopril
Vivatec
Z2786051707
Zestril
Zestril (TN)
ZINC3812863

US Patents and Regulatory Information for lisinopril

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sandoz LISINOPRIL lisinopril TABLET;ORAL 075903-005 Jul 1, 2002 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Apotex Inc LISINOPRIL lisinopril TABLET;ORAL 076102-005 Sep 30, 2002 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Lupin LISINOPRIL lisinopril TABLET;ORAL 077321-002 Sep 9, 2005 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for lisinopril

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck PRINIVIL lisinopril TABLET;ORAL 019558-004 Oct 25, 1988 ➤ Sign Up ➤ Sign Up
Merck PRINIVIL lisinopril TABLET;ORAL 019558-006 Jan 28, 1994 ➤ Sign Up ➤ Sign Up
Alvogen Malta ZESTRIL lisinopril TABLET;ORAL 019777-002 May 19, 1988 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Cantor Fitzgerald
Queensland Health
Cipla
Dow
Fuji
AstraZeneca
Accenture
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.